Market Overview

Verseon Interim Report Charts Progress of Development Programs as It Submits Phase I Protocol for Precision Anticoagulant

Share:

Verseon's drug discovery program, based on an industry-leading in
silico
platform, progresses four programs with multiple novel
compounds in anticoagulation, HAE, DME, and oncology.

Anticoagulants

Verseon has submitted the Phase I protocol for its lead precision oral
anticoagulant (PROAC) candidate, VE-1902, and expects to start
first-in-human trials in Q3 2018.

PROACs are potent, highly selective, reversible covalent inhibitors of
thrombin. They have shown excellent efficacy and low bleeding risk in
multiple preclinical studies but do not disrupt platelet function.
Therefore, they may be the first oral anticoagulants suitable for
long-term anticoagulant-antiplatelet combination therapy. Such treatment
is particularly relevant for tens-of-millions of patients worldwide with
acute coronary syndrome or non-valvular atrial fibrillation comorbid
with coronary artery disease.

Verseon's second PROAC candidate will enter the clinic in 2019.

Diabetic Macular Edema (DME)

Verseon also detailed progress with its oral plasma kallikrein
inhibitors for the treatment of diabetic macular edema (DME). These
small-molecule drug candidates are suitable for oral dosing and could
replace or complement the current standard DME treatment, which is
recurrent eye injections. An oral treatment would also be suitable for
ongoing preventative treatment.

The company expects to nominate the first candidate for development in
Q4 2018.

Hereditary Angioedema (HAE)

Verseon is also developing a number of oral plasma kallikrein inhibitors
for the treatment of hereditary angioedema (HAE), a rare and sometimes
life-threatening genetic disease characterized by recurring episodes of
swelling. Recent research has shown that plasma kallikrein is an
important target central to the HAE pathway.

Further development is planned to optimize the pharmacokinetic profiles
of these candidates and to test for in vivo efficacy.

Solid Tumors

Verseon is developing a class of next-generation chemotherapy agents for
the treatment of multidrug resistant cancers. These small-molecule
tubulin inhibitors have shown nanomolar in vitro potency against
a range of cancer cell lines. Further preclinical testing showed that
the tubulin inhibitors are only weakly affected by common modes of drug
resistance.

About Verseon

Verseon Corporation (www.verseon.com,
AIM: VSN) is a technology-based pharmaceutical company that pairs a
proprietary, computational drug discovery platform with a comprehensive
in-house chemistry and biology workflow to develop novel therapeutics
that are unlikely to be found using conventional methods.

-Ends-

View Comments and Join the Discussion!